Real-World Progression-Free Survival and Healthcare Resource Utilization Associated with Daratumumab Use in Transplant-Ineligible Multiple Myeloma Patients in Italy.

Clinicoecon Outcomes Res · 2026 · PMC13051186 · PMID 41948392

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Among patients treated with DaraRd, the differences in HCRU or costs associated with IV (N=64) and SC (N=113) administration did not reach statistical significance, though a favourable trend was observed for the SC route.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.